Thursday 24 October 2019

Leukemia Therapeutics Market size and Key Trends in terms of volume and value 2019

The Global Leukemia Therapeutics anticipated to have held a market value of USD 10.7 billion in the year 2017 and is expected to grow at a CAGR of 5.3% during the forecast period. Leukemia is blood cancer which most commonly in adults and children. Acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia are the major types of the leukemia. leukemia therapeutics such as chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant are used in treating the leukemia.
Availability of innovative therapies for leukemia, increasing number of cases of leukemia, strong developing pipeline and targeted drug delivery, and increasing older population are expected to drive the growth of market. According to the Leukemia & Lymphoma Society of Canada, in 2016 estimated 22,510 were suffer with leukemia in Canada and 5,900 new cases of leukemia founded in same year. On other hand, high cost required for the development of new therapeutics can restrain the market growth over the assessment period.
Segmentation
The global leukemia therapeutics market has been segmented into type, applications, and region.
Based on applications, leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others. The acute lymphocytic leukemia segment is expected to account for the largest share segment of the market in 2017.
Based on type, leukemia therapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.
Top Key Players
  • Eisai Co., Ltd (Japan)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Bristol-Myers Squibb Company (US)
  • Hoffmann-La Roche AG (Switzerland)
  • Sanofi S.A. (France)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Amgen Inc (US)
  • Takeda Pharmaceutical Company Ltd (Japan)
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.
Europe is expected to hold the second largest position in the global leukemia therapeutics market. The market growth in this region is attributed to increase prevalence of leukemia.
The leukemia therapeutics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.
The Middle East & Africa has the least share of the leukemia therapeutics market.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Wednesday 23 October 2019

Mixed Reality in Healthcare Market to Observe Strong Development by 2019

The global mixed reality in healthcare market is projected to show significant growth over the forecast period. It is estimated that the global mixed reality in healthcare market is expected to register a CAGR 26.3% during the forecast period of 2019 to 2024, with an estimated market value of USD 2,475 million in 2018.
Mixed Reality (MR) is an amalgamation of Augmented Reality (AR) and Virtual Reality (VR), defining the polar ends of a spectrum known as virtuality spectrum or mixed reality spectrum. Augmented reality delivers digital components, whereas virtual reality enables immersive imitation of real-life settings. MR has widespread applications in different fields of healthcare, varying from treatment to training and education. The global mixed reality in healthcare market is fueled by factors such as rapid improvements in the adoption of sensor technology, increase in the user acceptance, increased applications of MR in disease care and treatment, and increasing workload of healthcare professionals. Additionally, the benefits of MR systems such as operational efficiency, increased service quality, and reduced human effort is also projected to drive the growth of the mixed reality in healthcare market. For instance, in 2018, Samsung completed a randomized control trial that showed that VR therapy reduces pain by 52%.
On the other hand, the lack of adequate skill among medical practitioners, high investment costs, occurrences of technical glitches and the concern related to loss of data is likely to curb the growth of the market during the assessment period. Nevertheless, changes in regulatory policies are expected to reduce the impact of barriers over the forecast period.
Moreover, major companies in the market are involved in strategic acquisitions and collaborations to brace their position in the market. For instance, in March 2018, Samsung announced a partnership with Travelers Insurance, Cedars-Sinai Medical Center, Bayer, and AppliedVR to study a virtual reality for pain management.
Players Covered:
Some of the key players in the global mixed reality in healthcare market are Mindmaze, Atheer, Augmedix, Firsthand Technology, Daqri, Medical Realities, Google, Microsoft, Echopixel, Oculus VR, Orca Health, Psious, Samsung Electronics, Surgical Theatre LLC, and Osso VR.
Mixed Reality in Healthcare Market – Segments
The global mixed reality in healthcare market has been segmented into component, device type, application, and end user.
The market, based on component, has been segmented into software, hardware, and service. The software segment is expected to hold a major share due to the increased accessibility of software to the users, whereas the hardware segment is projected to be the fastest growing segment owing to ease of availability of hardware components.
The market, by device type, has been segmented into augmented reality in healthcare and virtual reality in healthcare. The AR in healthcare segment is expected to hold a major share due to the increased application of AR for the attenuation of pain perception, whereas VR in healthcare segment is anticipated to be the fastest growing segment owing to rise in awareness and increased research in this field. The market, by augmented reality in healthcare, has been further segmented into head-mounted display (HMD), and handheld device. The market, by virtual reality in healthcare, has been segmented into head-mounted display (HMD), gesture tracking devices, projectors, and others.
The market, by application, has been segmented into surgery simulation, surgery, patient care management, pharmacy care management, fitness management, and others. The surgery simulation segment is expected to hold a major share owing to the increasing use of MR tools for training surgeons due to the anatomically realistic recreations. The segment of surgery is expected to be the fastest growing segment due to the increased patient population in recent years.
The market, by end user, has been segmented into hospital and surgical centers, research organizations, and others. The segment of hospital and surgical centers is projected to hold a major share due to the rise in the hospitals switching to MR systems, whereas the segment of research organizations is expected to be the fastest growing segment due to the increased research initiatives.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The mixed reality in healthcare market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European mixed reality in healthcare market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The mixed reality in healthcare market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The mixed reality in healthcare market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Wise Analysis:
Geographically, the Americas is expected to dominate the global mixed reality in healthcare market due to the increasing per capita healthcare expenditure, and the heavy adoption of new technology. According to the research published in 2016 by Johns Hopkins University School of Medicine, it was estimated that if all US hospitals increased the number of minimally invasive procedures by 50%, nearly 3,600 complications could be avoided annually. Furthermore, rising expenses in research and investment by healthcare bodies are anticipated to drive the growth of the market in this region.
Europe showed a considerable amount of growth in the global mixed reality in healthcare market. The market growth in this region is because of the presence of a well-established healthcare system and increase in chronic diseases.
Asia-Pacific is expected to have a sturdy growth rate during the forecast period owing to the huge patient pool and government initiatives of healthcare reforms. In 2016, as a part of an ongoing neurosurgical collaboration between Children’s Hospital in Ho Chi Minh City (Vietnam) and Children’s of Alabama Hospital, a Virtual Interactive Presence and Augmented Reality (VIPAR) telecommunication system was implemented at both hospitals to provide intraoperative assistance to medical professionals. However, less capital investment is restricting the market growth of this region.
On the other hand, the Middle East & Africa has the least share of the market due to the low disposable income. Moreover, limited access to treatment facilities is also expected to curb the growth of the market in the near future.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312

Automatic Pill Dispenser Market up to 2023: Top Companies, Growth Factors Details and Regional Overview by Types & Application

Automatic Pill Dispenser Market Highlights:
The Global Automatic Pill Dispenser Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 1,700 million in 2018 and is projected to register a CAGR of 7.3% over the forecast period.
The increasing prevalence of cardiovascular disorders and growing older population are the key factors driving the automatic pill dispenser market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.
Request For a Free Sample Copy of Report at https://www.marketresearchfuture.com/sample_request/8008  
Various other factors such as the advancements in automatic pill dispenser, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on home care centers are also expected to propel the growth of the market.
However, the high cost of the system can hamper market growth over the forecast period.
Key Players:
Some of the key players in the global automatic pill dispenser market are Baxter International Inc, Becton, Dickinson and Company, Cerner Corporation, Capsa Healthcare, McKesson Corporation, Omnicell Inc., ScriptPro LLC, Swisslog Holdings AG, Yuyama Co.Ltd. Talyst, Inc., and others
Segmentation:
The global automatic pill dispenser market is segmented based on type, end user, and region.
The global market for automatic pill dispenser, by type, is segmented into a centralized, automated dispensing system, and decentralized the automated dispensing system. The centralized, automated dispensing system is further classified into robotic automated dispensing systems, and carousels. Furthermore, decentralized automated dispensing system is classified into a pharmacy-based automated dispensing system, ward-based automated dispensing system, and automated unit dose dispensing system.
Based on end user, the market is segmented into hospital pharmacy, retail pharmacy, and home healthcare.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The automatic pill dispenser market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European automatic pill dispenser market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The automatic pill dispenser market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The automatic pill dispenser market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Analysis:
The Americas dominated the global market for automatic pill dispenser owing to the rising geriatric population within the region. As per the data suggested by the United Census Bureau, by 2060, the US is projected to grow by 79 million people, from about 326 million today to 404 million. The population is projected to cross the 400-million threshold in 2058. Additionally, according to the WHO, in the US, more than 20% of the total population is likely to be aged 65 years or over by 2030. Rising participation of market players is also strongly impacting the growth of the Americas automatic pill dispenser market. Moreover, the rising prevalence of chronic disorders such as cardiovascular disorders, cancer, diabetes, and others are driving the growth of the market. For instance, according to the National Cancer Institute, in 2016, in the US, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care.
In 2018, it was estimated that Europe stood second in the global automatic pill dispenser market. Technological advancements, along with the availability of funding opportunities in research and innovation, will support market growth.
Browse Premium Research Report Enabled with Respective Tables And Figures At https://www.marketresearchfuture.com/reports/automatic-pill-dispenser-market-8008
Asia-Pacific (APAC) is expected to represent the phenomenal market growth throughout the forecast period due to rising prevalence of chronic conditions, growing awareness about medications, and increasing healthcare expenditure. During 2016-2017, Australia spent nearly USD181 billion on health, which is more than USD 7,400 per person and 10% of overall economic activity.
On the other hand, the Middle East and Africa held the least share in the global automatic pill dispenser market due to the low economic development, especially within the African region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future      
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028         
Maharashtra, India
Phone: +1 646 845 9312

Gene Expression Analysis Market Segmentation Detailed Study with Forecast Up To 2019

Market Scenario:
The Global Gene Expression Analysis Market is expected to grow significantly over the forecast period. It is estimated that the global gene expression analysis market is expected to hold a market value of USD 3.250 million and register a CAGR ~9.1% during the forecast period of 2018 to 2023. Gene expression analysis is research dedicated towards functional genomics extending the application purview of studying genes and gene transcripts. Synthesizing functional gene products such as functional RNAs and protein species offers insights on how an intact organism survives when a particular gene goes missing. Growth in personalized medicine and technological developments are driving market growth. According to a data published by the Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicines in 2017. Moreover, the development of genomic databases and increased government funding towards genomics is fueling market growth.
However, the lack of skilled labor and the high cost of instruments may hamper market growth during the assessment period.
Segmentation
The global gene expression analysis market has been segmented into product, services, application, end-user, and region.
The market, on the basis of product, has been segmented into consumables and instruments.
The market, based on consumables, has been further segmented into reagents and DNA chips.
The market, based on instruments, has been further segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others.
The market, by services, has been segmented into gene expression profiling services, sequencing services, bioinformatics solutions, and others.
The market, by application, has been segmented into drug discovery, diagnosis, research, and others.
The market, by end-user, has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gene expression analysis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gene expression analysis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The gene expression analysis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gene expression analysis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
  • GENERAL ELECTRIC COMPANY,
  • Illumina, Inc.,
  • Thermo Fisher Scientific,
  • Bio-Rad Laboratories, Inc.,
  • Hoffmann-La Roche Ltd,
  • Pacific Biosciences of California, Inc.,
  • BGI,
  • PerkinElmer Inc.,
  • Agilent Technologies, Inc.,
  • QIAGEN,
  • Oxford Gene Technology,
  • Eurofins Scientific,
  • Danaher,
  • Genotypic Technology Pvt Ltd,
  • Macrogen Inc.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global gene expression analysis market owing to the increasing research activities and the rising popularity of gene expression tests. Additionally, the well-developed healthcare sector is anticipated to boost the American gene expression analysis market.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing investment from governments in the field of genomics, and continuously developing economies. According to a report published by the International Journal of Social and Developmental Concerns in October 2017, in Malaysia, the growth of the public primary, as well as secondary care facilities, has decreased in the past few years, and it has not kept pace with the rapid urbanization. Thus, such factors restraint the growth of the market in this region. On the other hand, the Middle East & Africa has the least share of the market.
Europe is expected to hold the second largest position in the global gene expression analysis market. The market growth in this region is attributed to the availability of funds for research.
Browse Complete 160 Pages Premium Research Report Enabled with Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/gene-expression-analysis-market-7805
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Tuesday 22 October 2019

Optical Imaging Market size and Key Trends in terms of volume and value 2019

Optical imaging has the ability to improve point of care in the healthcare setting since it provides improved screening and detection of disease. The global optimal imaging market is anticipated to attain a valuation of USD 1.92 Bn at a CAGR of 10% over the forecast period of 2018-2023, projects Market Research Future (MRFR) in an extensive study.
Some of the Top Key Players in Optical Imaging Market are Jude Medical, Inc., Carl Zeiss Meditec AG, Bioptigen, Inc., Canon Inc, Heidelberg Engineering, Inc., Topcon Corporation, Perkinelmer, Inc., Koninklijke Philips N.V. and Agfa-Gevaert N.V. etc.
Get Free Sample Copy @https://www.marketresearchfuture.com/sample_request/6172
Driven by critical healthcare needs, optimal imaging is gaining traction as a detector technology. Optimal imaging is a technique where cellular and molecular function in a living body is interrogated with the help of light and the special properties of photons to obtain detailed images of organs and tissues.
Optical imaging is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of optical imaging techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market.
However, factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for optical imaging procedures restrict market growth.
Segmentation
The global optical imaging market is segmented on the basis of products, techniques, therapeutic area, application, and end-user. Considering the type of product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. On the basis of technique, the market is segmented into Optical Coherence Tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.
On a therapeutic area basis, it is segmented into neurology, oncology, ophthalmology, dentistry, cardiology, dermatology, and others. On account of application, the market is segmented into pre-clinical and clinical research, pathological imaging and intraoperative imaging. According to the end-user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Market Summary
In terms of geography, Americas dominates the market for optical imaging owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders about rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants key players also propel the market growth in this region. For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Thus, this huge patient pool is going to boost up the market growth during the forecast period.
Europe is the second largest market and holds a healthy share in the global optical imaging market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of optical imaging over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.
Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in optical imaging market in future.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/optical-imaging-market-6172
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Autoimmune Disease Treatment Market to Observe Strong Development by 2019

Market Scenario
According to CDC in 2013, there were 2.8 million traumatic brain injury visits to emergency department and hospitals. The emergency department visits of brain injury patients increased by 47% from 2007. Thus, increasing incidence of TBI drives the growth of the market. Furthermore, increasing geriatric population is likely to fuel the market to grow.  According to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older, and in 2060, 98.2 million are expected to be 65 years or older.  Such increasing trend in the geriatric population provides favorable backgrounds for the market to grow.
Ventilator-associated pneumonia is a type of lung infection caused to patients who are on ventilators. Ventilator-associated pneumonia is caused mainly due to lung disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP requires aggressive surveillance combined with the radiographic examination, bedside examination, and microbiologic examinations of respiratory secretions. Growing Intensive Care Unit Admissions due to rising prevalence of respiratory diseases, rising number of ICU beds and high incidence of traumatic injuries provides favorable backgrounds for the market to grow.
However, factors such as expensive diagnostic tests, high ventilator charges, inappropriate reimbursement scenario, risks associated with ventilators are expected to restrict the market growth during the forecast period.
Key players
Some of the key players for the global Ventilator-associated pneumonia market Merck & Co., Inc. (U.S.), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) and other.
Segmentation
The global Ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, and end-user. The Ventilator-associated pneumonia market, by diagnosis categorized into Clinical Examination, Radiological Examination, Microbiological Analysis and others. Microbiological Analysis is further sub-segmented into Blood and pleural fluid cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative cultures of airway specimens. Mode of treatment segment is segmented into Homecare, Hospital care, and others. On the basis of end-user, the market is segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers and Emergency Medical Services (EMS).      
Regional Market Summary
The Ventilator-associated pneumonia market is dominated by North America owing to the rising geriatric population within the region. The U.S. Census Bureau projected that in 2060, 19.7 million would be of age 85 or older. This influences the growth of this market in this region.
Asia Pacific was projected to be the fastest growing region for the global Ventilator-associated pneumonia market in 2017. The rising geriatric population, increasing healthcare expenditure and growing respiratory disorders in Asia is expected to drive market growth in this region. According to The Asian Development Bank (ADB), the geriatric population in Asia is estimated to reach 923 million by 2050. Thus, this provides favorable backgrounds for the Ventilator-associated pneumonia market to grow.
It is estimated that Europe stood second in the global Ventilator-associated pneumonia market owing to increasing prevalence of lung diseases. According to European respiratory society, more than 50% of deaths are due to lung diseases. Thus, increasing prevalence of lung diseases in this region influences the growth of this market in this region.
The Middle East and Africa holds the least share in the global Ventilator-associated pneumonia market due to the presence of stringent government policies, poor economies, under-developed healthcare infrastructure and low penetration of healthcare services, especially within the African region.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Autoimmune Disease Treatment Market Segmentation Detailed Study with Forecast Up To 2019

Autoimmune disease is a medical condition that causes abnormalities in the immune response and triggers damage to the healthy body tissues. The increasing prevalence of autoimmune diseases all over the world is generating high demand for effective treatments in the global market. As per the report published by Market Research Future (MRFR), the global autoimmune disease treatment market is anticipated to expand remarkably at a noteworthy CAGR of 11.2% during the forecast period of 2017-2023.
Autoimmune diseases are diseases caused by the immune system mistaking the body’s own tissue for foreign tissues and attacking it. This can happen due to a number of complications within the immune system and can have disastrous consequences on the health of the individual. Some of the most widely prevalent autoimmune diseases include rheumatoid arthritis, lupus, and multiple sclerosis. Growing awareness about autoimmune diseases and their treatment is likely to be a major driver for the global autoimmune disease treatment market over the forecast period. While autoimmune diseases have always been present among human populations, their sporadic appearance and lack of infectiousness made them relatively minor subjects of study compared to other, more imminent threats. The growing prevalence of autoimmune diseases in modern times has led to growing awareness about the disease and is likely to remain the key driver for the autoimmune disease treatment market over the forecast period.
Growing development of effective treatments for a number of autoimmune diseases is likely to be a major driver for the global autoimmune disease treatment market over the forecast period. Autoimmune diseases can be hard to treat effectively, as treating them effectively means shutting down or slowing down the operations of the body’s immune system. While this may be an effective way of combating autoimmune diseases, this can also leave the body vulnerable to other infections and diseases that can make the most of the body’s temporary weakness. The use of genetic components in treating autoimmune diseases is a new aspect gained by the autoimmune disease treatment market in the last few years and is likely to remain a key part of the market over the forecast period due to the increasing awareness about its effectiveness and safety.
Competitive Dashboard:
Some of the prominent players profiled in this MRFR report are
  • Abbott Laboratories,
  • Genentech Inc.,
  • Bayer Schering Pharma AG,
  • Amgen Inc.,
  • Biogen Idec Inc.,
  • Chugai Pharmaceutical Co. Ltd.,
  • Danaher,
  • Bio-Rad,
  • Elan Corporation Plc,
  • Hoffmann-La Roche AG,
  • GlaxoSmithKline Plc,
  • HYCOR Biomedical,
  • Eli Lilly and Company,
  • Johnson & Johnson Inc.,
  • Siemens,
  • Squibb Company,
  • Merck & Co. Inc.,
  • Thermo Fisher Scientific.
Segmental Analysis:
By disease type, the global autoimmune disease treatment market has been segmented into localized, and systemic. The localized segment is further sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.
By diagnosis, the autoimmune disease treatment market has been segmented into ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.
By therapeutic products, the global autoimmune disease treatment market has been segmented into drugs and therapeutic and monitoring equipment. The drugs segment is further sub-segmented into biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.
By distribution channel, the autoimmune disease treatment market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Outlook:
The Americas dominate the autoimmune disease treatment market owing to the rising cases of autoimmune diseases, and high healthcare expenditure. As per the data suggested by Centers for Disease Control and Prevention in 2015, the total healthcare expenditure in the U.S. was reported to be USD 3.2 trillion, whereas, hospital care accounted for a share of 32.3%.
Europe holds the second position in the autoimmune disease treatment market. It is expected that the financial support provided by the government bodies for research & development and amendments in reimbursement policies in the healthcare is likely to drive the European market
Owing to a huge patient pool and developing healthcare technology, Asia Pacific is the fastest growing autoimmune disease treatment market. Healthcare expenditure is also found to be escalating in various Asia Pacific countries. The Australian Institute of Health and Welfare suggested that in the year 2015-2016, the total healthcare expenditure was USD 170.4 billion, which is around 3.6% higher than the expenditure during 2014-2015.
The Middle East & Africa holds the lowest market due to poor medical facilities, and lack of technical knowledge.
Industry News:
  • In January 2019, Cabaletta Bio, launched out of the University of Pennsylvania, has raised USD 50 Mn for the treatment of for cell-based autoimmune disease.
  • In January 2019, Banner Life Sciences LLC, a privately held specialty pharmaceutical company, has received tentative approval by the U.S. Food and Drug Administration (FDA) for BAFIERTAM developed for the treatment of relapsing forms of Multiple Sclerosis.
     
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com